ClinicalTrials.gg
CompletedNCT04162743Updated Apr 6, 2020

The Effect of Trazodone on the Severity of Obstructive Sleep Apnea in Insomnic Stroke Patients With Depression

A Phase 4 interventional study of Trazodone and Placebo oral tablet in Sleep Apnea Syndromes and Cerebral Infarction, sponsored by Chang Gung Memorial Hospital. Completed at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-04-06.

Sponsored by Chang Gung Memorial Hospital · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Feb 2019, registered Nov 2019).
Phase
Phase 4
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

The investigators hypothesize that trazodone does not worse nocturnal oxygen saturation in insomnic ischemic stroke patients with obstructive sleep apnea (OSA) and depression and has beneficial effect in selected stroke patients with low arousal threshold phenotype OSA.

02

Conditions studied

  • Sleep Apnea Syndromes
  • Cerebral Infarction
03

In context

Sleep Apnea Syndromes

2,183 studies on the registry are indexed under Sleep Apnea Syndromes; 284 are open to participants now.

This study's enrollment of 22 is below the median of 53 across 1,400 interventional studies indexed under Sleep Apnea Syndromes.

Browse Sleep Apnea Syndromes studies →

Lead sponsor

Chang Gung Memorial Hospital is the lead sponsor of 1,091 studies on the registry; 238 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Insomnic ischemic stroke patients with OSA and depression.

Exclusion criteria

Exclusion Criteria:

  • unclear consciousness, unstable vital sign or neurologic sign, unstable medical conditions such as delirium, active infection, evidence of overt congestive cardiac failure, liver dysfunction with ascites, thyroid disease, end-stage-renal-disease receiving dialysis.
  • overnight mean oxygen saturation (SaO2) nadir is ≤ 70% at baseline
  • take monoamine oxidase inhibitors (MAOI), any medication that may affect breathing, sleep, or muscle activity
  • any known allergy to trazodone
  • sleep disorder other than OSA (e.g., periodic leg movement syndrome, restless legs syndrome, central sleep apnea/Cheyne-Stokes respiration).
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
22 participants (actual)

Study arms

  • Active comparator
    Trazodone

    take trazodone 100mg hs

    Drug: Trazodone

  • Placebo comparator
    Placebo

    take placebo pill hs

    Drug: Placebo oral tablet

Interventions

  • take trazodone 100mg before polysomnography

  • DrugPlacebo oral tablet

    take placebo oral tablet before polysomnography

06

What researchers measure

Primary outcomes

  1. nocturnal oxygen saturation

    mean and minimum oxyhemoglobin saturation (%) detected by pulse oximetry during polysomnography study

    Time frame: the polysomnography study night before take drug

  2. Sleep apnea severity index

    apnea-hypopnea index, desaturation index according to The American Academy of Sleep Medicine (AASM) scoring manual version 2.0.3: Obstructive apnea: no airflow \>= 10 s with respiratory effort (per hour of time); central apnea: no airflow without respiratory effort (per hour of time). Hypopnea: airflow decrease \>30% lasting \>= 10 s, followed by either oxygen desaturation \> 3% or EEG arousal (per hour of time). The desaturation index: number of desaturations per hour of time.

    Time frame: the polysomnography study night before take drug

07

Study locations

1 site
  • Chang Gung Memorial Hospital, Keelung
    Keelung, Taiwan
08

References and documents

Publications

  • Chen CY, Chen CL, Yu CC. Trazodone improves obstructive sleep apnea after ischemic stroke: a randomized, double-blind, placebo-controlled, crossover pilot study. J Neurol. 2021 Aug;268(8):2951-2960. doi: 10.1007/s00415-021-10480-2. Epub 2021 Feb 24. PubMed 33625584 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04162743
Responsible party
CHEN,CHUNG YAO (doctor, Chang Gung Memorial Hospital) — Principal investigator
First posted
Nov 14, 2019
Start date
Feb 1, 2019
Primary completion
Mar 31, 2020
Completion
Mar 31, 2020
Last update
Apr 6, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trazodone

Start the discussion